FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911656502> ?p ?o ?g. }

• W2911656502 endingPage "88" @default.
• W2911656502 startingPage "77" @default.
• W2911656502 abstract "The safety profile of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) is well established. TCZ was approved to treat giant cell arteritis (GCA) in 2017 in the USA and Europe, and its safety profile in patients with GCA continues to be defined. The objective of this analysis was to examine incidence rates (IRs) of adverse events of special interest (AESI) occurring during the TCZ clinical development program and in healthcare claims data in patients with GCA or RA.TCZ-naïve patients with GCA or RA were identified in the MarketScan administrative healthcare claims database. TCZ-treated patients with GCA from the GiACTA trial and TCZ-treated patients with RA from pooled clinical trial data were analyzed. The IRs of AESI (AESI IRs) were calculated for all cohorts. In the claims cohorts, risks of AESI were estimated using Poisson regression.TCZ-naïve claims cohorts comprised 4804 patients with GCA [mean (standard deviation) age 73.4 (9.8) years; follow-up 3.9 (3.1) years] and 15,164 patients with RA [age 60.3 (8.2) years; follow-up, 4.5 (2.8) years]. TCZ-treated clinical trial cohorts comprised 149 patients with GCA [age 69.5 (8.4) years; exposure approx. 138 patient-years (PY)] and 7647 with RA [age 52 (12.6) years; exposure approx. 22,394 PY]. The IRs of infections, stroke, malignancies, myocardial infarction, and gastrointestinal perforations in the GCA claims cohort exceeded those in the RA claims cohort; the risk of AESI (adjusted for age and glucocorticoid use) was higher in patients with GCA than in those with RA. Similar patterns to the claims cohorts in terms of the AESI IRs were observed in clinical trial cohorts, although the number of events was limited in the GCA trial cohort.Higher IRs of AESI were observed in patients with GCA versus those with RA in both TCZ-naïve and -treated cohorts. Differences in underlying disease, age, and glucocorticoid use may influence AESI incidence, irrespective of intervention.This study was funded by F. Hoffmann-La Roche Ltd and Genentech, Inc. Article processing charges were funded by F. Hoffmann-La Roche Ltd. Plain language summary is available for this article." @default.
• W2911656502 created "2019-02-21" @default.
• W2911656502 creator A5012591907 @default.
• W2911656502 creator A5018367518 @default.
• W2911656502 creator A5029143005 @default.
• W2911656502 creator A5040865719 @default.
• W2911656502 creator A5041844509 @default.
• W2911656502 creator A5042482253 @default.
• W2911656502 creator A5062719461 @default.
• W2911656502 creator A5071962255 @default.
• W2911656502 creator A5072713876 @default.
• W2911656502 creator A5087072990 @default.
• W2911656502 date "2019-02-01" @default.
• W2911656502 modified "2023-10-10" @default.
• W2911656502 title "Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data" @default.
• W2911656502 cites W1277855217 @default.
• W2911656502 cites W1488642175 @default.
• W2911656502 cites W1788988135 @default.
• W2911656502 cites W1838548883 @default.
• W2911656502 cites W1975297209 @default.
• W2911656502 cites W1987316799 @default.
• W2911656502 cites W1995278898 @default.
• W2911656502 cites W2003578638 @default.
• W2911656502 cites W2015410646 @default.
• W2911656502 cites W2031514617 @default.
• W2911656502 cites W2049234314 @default.
• W2911656502 cites W2054059257 @default.
• W2911656502 cites W2063485775 @default.
• W2911656502 cites W2069962584 @default.
• W2911656502 cites W2082567437 @default.
• W2911656502 cites W2096862304 @default.
• W2911656502 cites W2097874407 @default.
• W2911656502 cites W2101528090 @default.
• W2911656502 cites W2102207725 @default.
• W2911656502 cites W2112777125 @default.
• W2911656502 cites W2113398090 @default.
• W2911656502 cites W2114308202 @default.
• W2911656502 cites W2127445888 @default.
• W2911656502 cites W2133915381 @default.
• W2911656502 cites W2134765554 @default.
• W2911656502 cites W2146831240 @default.
• W2911656502 cites W2150952126 @default.
• W2911656502 cites W2171795919 @default.
• W2911656502 cites W2177530838 @default.
• W2911656502 cites W2268527577 @default.
• W2911656502 cites W2272386525 @default.
• W2911656502 cites W2340298857 @default.
• W2911656502 cites W2415454392 @default.
• W2911656502 cites W2498871550 @default.
• W2911656502 cites W2523519404 @default.
• W2911656502 cites W2553035171 @default.
• W2911656502 cites W2558363236 @default.
• W2911656502 cites W2737436316 @default.
• W2911656502 cites W2783691170 @default.
• W2911656502 cites W2799432007 @default.
• W2911656502 cites W2805740714 @default.
• W2911656502 doi "https://doi.org/10.1007/s40744-019-0139-5" @default.
• W2911656502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6393272" @default.
• W2911656502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30707391" @default.
• W2911656502 hasPublicationYear "2019" @default.
• W2911656502 type Work @default.
• W2911656502 sameAs 2911656502 @default.
• W2911656502 citedByCount "14" @default.
• W2911656502 countsByYear W29116565022020 @default.
• W2911656502 countsByYear W29116565022021 @default.
• W2911656502 countsByYear W29116565022022 @default.
• W2911656502 countsByYear W29116565022023 @default.
• W2911656502 crossrefType "journal-article" @default.
• W2911656502 hasAuthorship W2911656502A5012591907 @default.
• W2911656502 hasAuthorship W2911656502A5018367518 @default.
• W2911656502 hasAuthorship W2911656502A5029143005 @default.
• W2911656502 hasAuthorship W2911656502A5040865719 @default.
• W2911656502 hasAuthorship W2911656502A5041844509 @default.
• W2911656502 hasAuthorship W2911656502A5042482253 @default.
• W2911656502 hasAuthorship W2911656502A5062719461 @default.
• W2911656502 hasAuthorship W2911656502A5071962255 @default.
• W2911656502 hasAuthorship W2911656502A5072713876 @default.
• W2911656502 hasAuthorship W2911656502A5087072990 @default.
• W2911656502 hasBestOaLocation W29116565021 @default.
• W2911656502 hasConcept C120665830 @default.
• W2911656502 hasConcept C121332964 @default.
• W2911656502 hasConcept C126322002 @default.
• W2911656502 hasConcept C167704817 @default.
• W2911656502 hasConcept C197934379 @default.
• W2911656502 hasConcept C2776015282 @default.
• W2911656502 hasConcept C2776712624 @default.
• W2911656502 hasConcept C2777178219 @default.
• W2911656502 hasConcept C2777575956 @default.
• W2911656502 hasConcept C2779134260 @default.
• W2911656502 hasConcept C44249647 @default.
• W2911656502 hasConcept C535046627 @default.
• W2911656502 hasConcept C61511704 @default.
• W2911656502 hasConcept C71924100 @default.
• W2911656502 hasConcept C72563966 @default.
• W2911656502 hasConceptScore W2911656502C120665830 @default.
• W2911656502 hasConceptScore W2911656502C121332964 @default.
• W2911656502 hasConceptScore W2911656502C126322002 @default.
• W2911656502 hasConceptScore W2911656502C167704817 @default.

• next